NeurAxis (NRXS) Q2 2026 earnings review
CPT Code Execution Triggers Triple-Digit Growth, But OpEx Creeps Up
NeurAxis delivered a massive 116% YoY revenue acceleration in Q2, proving that the January 1 activation of its Category I CPT code is functioning exactly as intended. The code catalyzed a critical mix shift: the company is aggressively swapping out deeply discounted financial assistance volume for high-margin, fully reimbursed commercial procedures. This dynamic expanded gross margin by 230 basis points to 85.9%. However, the cost of capturing this newly unlocked market is rising. Operating expenses spiked to $3.8M, widening the net loss by 23% YoY. The company is actively choosing top-line saturation over near-term profitability, a logical move given the massive untapped addressable market, but one that will keep cash burn elevated in the second half of the year.
🐂 Bull Case
The transition from discounted channels to full-reimbursement payers is working. Average Selling Price (ASP) for IB-Stim jumped 30% YTD to $1,003, structurally upgrading the company's gross margin profile to the mid-80s.
Despite launching in only three small territories initially, the VA channel generated multiple unforecasted orders. The deployment of ten dedicated 1099 reps by mid-September unlocks a 7-million-patient system completely isolated from commercial payer bottlenecks.
🐻 Bear Case
Management explicitly guided that cash burn will 'tick up in the second half of the year' to fund aggressive commercial hiring. With $8.3M in cash and a Q2 burn of $1.0M, the runway is healthy, but the pivot back to higher burn delays the breakeven narrative.
The company admits they are treating 'virtually no one' relative to the total addressable market. Broad adoption remains entirely hostage to securing written medical policies from the remaining 4-5 major national insurers.
⚖️ Verdict: 🟢
Bullish. The 116% revenue growth proves the core thesis: when reimbursement friction is removed, hospitals will aggressively adopt IB-Stim. While the rising OpEx warrants monitoring, management's decision to saturate covered markets rather than hoard cash is the right strategic maneuver.
Key Themes
Category 1 CPT Code Flips the Revenue Mix
The January 1 effective date for the Category 1 CPT code is the foundational driver of NeurAxis's current acceleration. Unit deliveries increased 60% YoY, but revenue grew 116% YoY. This divergence is entirely due to the mix shift away from the discounted financial assistance program and toward full-reimbursement payers. This structural upgrade is accelerating revenue while strictly defending margins.
Strategic Pivot to 'Depth Over Breadth'
Management is explicitly refusing to expand broadly into states lacking payer coverage. Instead, they are concentrating capital into a 'strategic market initiative' within the 6-8 states that have optimal policy coverage. By deploying specialized MSLs, digital marketing, and pediatric psychology directors directly into these high-coverage clusters, the company expects to drive immediate, highly predictable utilization.
Aggressive VA Commercialization via 1099 Network
Management has rapidly escalated its Veterans Affairs (VA) strategy. After seeing unprompted demand in Q1/Q2, the company hired 10 independent (1099) sales reps to specifically target the VA. This model—paying commissions only upon successful device sales—limits fixed OpEx while attacking a 7-million-patient federal system that bypasses the commercial insurance roadblocks.
Operating Expense Spike Contradicts 'Leverage' Narrative
While management previously touted operating leverage, Q2 saw total operating expenses surge to $3.8M. Selling expenses shot up 61% YoY to $861K, and G&A surged 46% to $2.6M (driven by stock comp and advisory fees). While revenue grew faster (+116%), the absolute dollar increase in OpEx entirely absorbed the gross profit gains, resulting in a 24% YoY deterioration in operating loss. Growth is expensive.
Medicaid Implementation Delays
Despite having the federal CPT code in place, Medicaid access remains a bureaucratic bottleneck. Many states have yet to load CPT code 64567 onto their 2026 fee schedules. Because Medicaid often makes up 20-40% of a children's hospital's payer mix, these administrative implementation gaps are stalling complete institutional rollouts due to hospital 'health equity' concerns (refusal to treat commercial patients if Medicaid patients are excluded).
Hospital Capacity & Clinic Bottlenecks
A structural headwind has emerged at the hospital level. Even in accounts with excellent insurance coverage and physician buy-in, patients are facing multi-month wait times simply because hospital administrators have not allocated enough physical clinic space or dedicated scheduling blocks for IB-Stim procedures. Overcoming this requires NeurAxis to educate hospital C-suites on the positive procedural economics.
Other KPIs
Accelerating. ASP is up 30% YoY from $772 in the first half of 2025. This metric is the clearest indicator that the Category I CPT code is successfully transitioning the company out of its heavily discounted financial assistance program and into full commercial reimbursement tiers.
Accelerating. Up significantly from 12% at the same point in 2025. This nearly 3x improvement directly correlates with the new CPT code and expanding medical policy coverage, removing the primary friction point for physicians prescribing IB-Stim.
Accelerating. Up 68% from $24,000 YTD in 2025. Combined with a 16% increase in total ordering accounts (88 vs 76), this proves the commercial strategy of driving 'depth' within existing, covered accounts is yielding immediate results.
Guidance
Reversing. After averaging a highly efficient $1.1M quarterly burn rate in H1 2026, the CFO explicitly guided that cash burn will increase in H2. This is driven by aggressive hiring (sales reps, market access VP, MSLs) to capitalize on recent payer momentum. With $8.3M in cash, liquidity is safe, but the timeline to free-cash-flow breakeven is extended as the company prioritizes land-grab market share.
Key Questions
Payer Coverage Timeline
You noted 'significant gains' with two large key commercial payers. Given the lengthy administrative process of moving from verbal agreement to written, published medical policy, what is the realistic timeline for these policies to go live and impact hospital utilization?
VA 1099 Rep Economics
With 10 new 1099 reps entering the field by mid-September, what is the expected ramp time for these territories, and what target revenue per rep do you need to see to justify expanding this model nationally in early 2027?
Medicaid Fee Schedule Resolution
How many key states are currently lagging in loading the 64567 CPT code onto their Medicaid fee schedules, and what specific levers can your new VP of Healthcare Economics pull to accelerate this state-level administrative process?
Operating Expense Trajectory
With the recent Q2 OpEx spike and guidance for higher cash burn in H2, what is the new normalized quarterly operating expense run-rate investors should model moving forward?